Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies. (QoL Phase I)
A prospective cohort of 250 patients with solid tumours included in phase I clinical trials of targeted agents will be enrolled. Patients will be treated with MTA in mono therapy or in association with chemotherapy or other targeted agents in 4 large phase I centers.
Patients from trials investigating chemotherapy alone will not be included. Quality of life will be assessed during the treatment period.
Visão geral do estudo
Status
Condições
Descrição detalhada
The main objective of phase I dose finding studies is to identify the recommended phase II dose. The primary endpoint is the dose limiting toxicity (DLT) which is generally measured using the NCI common toxicity criteria (NCI-CTCAE) graded scale. This scale, developed for the investigation of cytotoxic chemotherapy administered in a limited number of cycles including rest period, is well adapted to identify the drug effect on organ dysfunction and life threatening events. However it may be less relevant to reflect the patient's feeling regarding the tolerability of the treatment under study resulting in over or under estimation of these toxicities.
Moreover, targeted therapies and more specifically the ones administered orally are given over long periods often with continuous schedules. Moderate toxic side effects lasting over a long period are usually not considered as DLT. The health related quality of life of patients as well as other patient reported outcome including symptom scale in addition to usual NCI CTCAE scale could be a relevant variable to detect intolerable treatments. It has not been studied prospectively to date in phase I trials.
A prospective cohort of 250 patients with solid tumours included in phase I clinical trials of targeted agents will be enrolled. Patients will be treated with MTA in mono therapy or in association with chemotherapy or other targeted agents in 4 large phase I centers.
Patients from trials investigating chemotherapy alone will not be included.
Patients included in a phase I trial will be requested to fill in
- a questionnaire of health related quality of life (the EORTC PAL 15 questionnaire)
- a questionnaire of symptoms (MDASI)
- a questionnaire on symptoms specific of MTA at baseline and at each cycle of treatment and 6 weeks after the end of treatment.
The sponsor of the therapeutic phase I trials will be informed that the present research is running and that it will not interfere with their investigational protocol. Each phase I center has the latitude to propose or not the health-related quality of life research to patients included in a given phase I trial.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: Patricia TRESCA, MD
- Número de telefone: +33.1.56.24.56.30
- E-mail: chrystelle.gastrin@curie.fr
Locais de estudo
-
-
-
Dijon, França
- Recrutamento
- Centre Georges Francois Leclerc
-
Paris, França, 75005
- Recrutamento
- Institut Curie
-
Toulouse, França
- Recrutamento
- Centre Claudius Régaud
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients with refractory solid tumor.
- Patient included in a dose finding phase I trial investigating at least one molecularly targeted agent as defined as anticancer agents that selectively target molecular pathways (including monoclonal antibodies) as opposed to DNA, tubulin or cell division machinery will be eligible.
- Phase I/II clinical trials with a dose finding component are also eligible. Trials investigating combinations of MTA with one or several cytotoxic agent(s) are eligible, as well as combinations of MTAs.
Exclusion Criteria:
- Patients with malignant hematologic disease will not be eligible.
Patients included in the following types of phase I trials are not eligible:
- Trials investigating hormonal therapy and biological therapeutics such as immunotherapy, gene therapy and vaccines alone or in combination;
- Trials of cytotoxic agents only;
- Trials investigating radiochemotherapy alone or in combination with chemotherapy or MTA
- Trials whose objectives do not include dose-finding. This includes pharmacokinetic only trials, bioequivalence trials, feasibility trials etc.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To evaluate the association between HR QoL, patient reported symptoms and DLT.
Prazo: up to six months
|
To evaluate whether some toxic side events that are non dose limiting according to the phase I protocol are reported as intolerable by the patients using either specific HR QoL questionnaires or patient reported scales of symptoms
|
up to six months
|
|
Patient interviews : qualitative comparison versus EORTC PAL 15 questionary
Prazo: Up to six months
|
Identify if some dimensions of the quality of life affected by the treatment are not captured by the EORTC PAL 15 questionaries. Interviews will be realized on a sub sample of patients. An explorative qualitative research could evaluate patients' experience of the impact, burden, tolerability or acceptability of phase I anti-cancer drug trials addressing patients' perception of symptoms, functioning and overall quality of life. Interviews results contrasted with the PAL15 questionnaires will enable to determine whether a QoL questionnaire dedicated to phase I trials is necessary and what are the main components felt essential to the patients. |
Up to six months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Xavier PAOLETTI, PhD, Gustave Roussy, Cancer Campus, Grand Paris
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- IC 2013-07
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Qualidade de vida
-
Aalborg UniversityConcluídoUltrassonografia Point of Care (POCUS)Dinamarca
-
Sorbonne UniversityAalborg UniversityRecrutamentoUltrassom Point of CareFrança
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalConcluídoUltrassom Point of CareUruguai
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaDesconhecidoUltrassom Point of CarePaquistão
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...ConcluídoTransgênero, HIV Continuum of CareEstados Unidos
-
Thomas Jefferson UniversityRecrutamentoVentilação mecânica | Ultrassom Point of Care | Oxigenação | Ventilação Manual | Distúrbio da função cardíaca pós-operatórioEstados Unidos
-
Hospital for Special Surgery, New YorkRecrutamentoPeptídeo 1 semelhante ao glucagon | Ultrassom Gástrico | Ultrassom Point of CareEstados Unidos, Canadá
-
Queens College, The City University of New YorkRecrutamentoPublicação de artigos submetidos ao American Journal of Public HealthEstados Unidos
-
Tanta UniversityDesconhecidoDiâmetro da bainha do nervo óptico | Ultrassom Point of CareEgito
-
Johann Wolfgang Goethe University HospitalConcluídoFormação de Coágulos e Agregação de Plaquetas em Testes Point of CareAlemanha